Zydus Lifesciences Ltd Upgraded to Hold by MarketsMOJO on Improved Technicals and Valuation

Quality Assessment: Strong Fundamentals Amidst Recent Challenges

Zydus Lifesciences continues to demonstrate robust long-term fundamental strength despite a recent negative financial performance in Q3 FY25-26. The company maintains a low debt profile with an average Debt to Equity ratio of just 0.05 times, underscoring prudent financial management. Its ability to generate shareholder value remains impressive, with an average Return on Equity (ROE) of 17.34%, signalling efficient utilisation of equity capital.

Operating profit margins have held steady, with a compound annual growth rate of 22.94%, while net sales have grown at an annual rate of 12.37%. The Return on Capital Employed (ROCE) stands at a healthy 23.72%, reflecting effective capital deployment. However, recent quarterly results showed some strain, with interest costs rising sharply by 43.34% to ₹231.20 crores and the operating profit to interest coverage ratio falling to a low of 13.98 times. The half-year ROCE also dipped to 20.07%, indicating some short-term pressure on profitability.

Despite these headwinds, Zydus Lifesciences remains among the top 1% of companies rated by MarketsMojo across over 4,000 stocks, highlighting its enduring quality credentials.

Valuation Upgrade: From Fair to Attractive

The valuation grade for Zydus Lifesciences has been upgraded from fair to attractive, reflecting improved relative value metrics compared to its pharmaceutical peers. The company currently trades at a price-to-earnings (PE) ratio of 18.08, which is reasonable given its sector and growth prospects. Its price-to-book value stands at 3.71, while the enterprise value to EBITDA ratio is 11.97, both indicating a more appealing valuation than many competitors.

Other valuation metrics reinforce this view: the enterprise value to capital employed ratio is a modest 3.46, and the PEG ratio is 1.25, suggesting that earnings growth is reasonably priced. The dividend yield of 1.18% adds to the stock’s appeal for income-focused investors. When compared to peers such as Lupin (PE 17.77, EV/EBITDA 11.32) and Glenmark Pharma (PE 26.17, EV/EBITDA 14.28), Zydus Lifesciences offers a competitive valuation with solid fundamentals.

This valuation upgrade is a key factor in the overall rating improvement, signalling that the stock is now more attractively priced for investors seeking exposure to the pharmaceuticals and biotechnology sector.

Financial Trend: Mixed Signals but Long-Term Growth Intact

While the recent quarter showed some financial softness, the broader financial trend for Zydus Lifesciences remains positive. The company’s net sales and operating profit have grown steadily over the years, with net sales increasing at an annualised rate of 12.37% and operating profit at 22.94%. Over the past year, profits have risen by 14.4%, supporting a PEG ratio that remains within reasonable bounds.

In terms of returns, the stock has outperformed the Sensex and BSE500 indices over multiple time horizons. For instance, the stock generated a 4.99% return over the last year compared to the Sensex’s -9.55%, and an impressive 81.29% return over three years versus the Sensex’s 20.20%. Even over a decade, the stock’s 179.13% return is close to the Sensex’s 189.10%, underscoring its long-term resilience.

However, the recent increase in interest expenses and the decline in operating profit to interest coverage ratio highlight some short-term financial pressures. Investors should monitor upcoming quarterly results closely to assess whether these are temporary setbacks or indicative of a longer-term trend.

Technical Analysis: From Mildly Bearish to Sideways

The technical grade for Zydus Lifesciences has improved from mildly bearish to sideways, reflecting a stabilisation in price momentum after recent volatility. Key technical indicators present a mixed but cautiously optimistic picture. On the weekly chart, the MACD is mildly bullish, supported by a mildly bullish KST and positive signals from Dow Theory and On-Balance Volume (OBV). Conversely, the monthly MACD and KST remain mildly bearish, while the Relative Strength Index (RSI) shows no clear signal on either timeframe.

Bollinger Bands indicate a mildly bullish trend on the weekly scale but sideways movement monthly, suggesting consolidation. Daily moving averages remain mildly bearish, reflecting short-term caution among traders. The stock’s price has fluctuated between ₹928.35 and ₹998.65 today, closing at ₹930.75, down 2.71% from the previous close of ₹956.65. The 52-week high and low stand at ₹1,059.00 and ₹835.85 respectively, indicating a moderate trading range.

This technical transition to sideways suggests that while the stock is no longer in a clear downtrend, it has yet to establish a strong upward momentum. Investors may view this as a period of consolidation before a potential breakout or further correction.

Market Position and Shareholder Structure

Zydus Lifesciences is classified as a mid-cap company within the Pharmaceuticals & Biotechnology sector, with a current market price of ₹930.75. The stock has demonstrated market-beating performance over the medium and long term, outperforming the BSE500 index over the last one year, three years, and beyond. Promoters remain the majority shareholders, providing stability and strategic direction.

The company’s Mojo Score stands at 54.0, with the Mojo Grade upgraded to Hold from Sell as of 12 May 2026. This reflects a balanced view that recognises both the company’s strengths and the challenges it faces in the near term.

Conclusion: A Balanced Upgrade Reflecting Improved Valuation and Technicals Amidst Mixed Financials

The upgrade of Zydus Lifesciences Ltd’s investment rating from Sell to Hold is driven primarily by an improved valuation grade and a stabilising technical outlook. While the company’s recent quarterly financials have shown some deterioration, its strong long-term fundamentals, low debt levels, and consistent profitability underpin the positive view.

Valuation metrics now suggest the stock is attractively priced relative to peers, and technical indicators point to a sideways consolidation phase rather than a continuation of the previous bearish trend. Investors should weigh these factors carefully, considering the company’s market-beating returns over multiple timeframes and its solid capital efficiency.

Overall, Zydus Lifesciences presents a compelling case for cautious optimism, warranting a Hold rating as it navigates short-term challenges while maintaining a strong foundation for future growth.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today